Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial
Titel:
Toripalimab (anti-PD-1) versus high-dose interferon-α2b as adjuvant therapy in resected mucosal melanoma: a phase II randomized trial
Auteur:
Lian, B. Si, L. Chi, Z.H. Sheng, X.N. Kong, Y. Wang, X. Tian, H. Li, K. Mao, L.L. Bai, X. Tang, B.X. Yan, X.Q. Li, S.M. Zhou, L. Dai, J. Tang, X.W. Ran, F.W. Yao, S. Guo, J. Cui, C.L.